COMP <GO>
CLVT vs GDRX // EV/EBITDA & P/E VALUATION
Clarivate Plc (NYSE) VS. GoodRx Holdings Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: CLVT 1
— GDRX 8
▲ EV/EBITDA & P/E VALUATION LEADER: CLVT
LAST: $1.72 (-2.27%) • MKT CAP: $1.10B
valuation
2.6x
LAST: $3.54 (+2.02%) • MKT CAP: $1.21B
valuation
15.8x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLVT VS. GDRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CLVT | GDRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 66.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 1.30% | 8.30% | -7.00 | GDRX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 2.6x | 15.8x | -13.20 | CLVT | /valuation <GO> |
| Free Cash Flow Yield | — | 13.61% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 2.90% | 11.00% | -8.10 | GDRX | /operating-margins <GO> |
| Net Profit Margin | -8.20% | 3.80% | -12.00 | GDRX | /net-margins <GO> |
| Revenue Growth (YoY) | -4.00% | 0.60% | -4.60 | GDRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 0.63 | -0.43 | GDRX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | GDRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.1 | 52.3 | -11.16 | GDRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 36.9x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.10B | $1.21B | -$107.4M | GDRX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CLVT REV | GDRX REV | CLVT GROSS % | GDRX GROSS % | CLVT FCF | GDRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.46B | $796.9M | 66.0% | — | $365.3M | $164.4M |
| FY 2024 | $2.56B | $792.3M | 66.0% | — | $357.5M | $182.7M |
| FY 2023 | $2.63B | $750.3M | — | — | $744.2M | $138.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLVT // BETA —
GDRX // BETA —